Home » Posts tagged with » Germany
Takeda Pharmaceutical opens €130m vaccine manufacturing plant in Germany

Takeda Pharmaceutical opens €130m vaccine manufacturing plant in Germany

Takeda Pharmaceutical Company opened a new €130 million vaccine manufacturing plant in Germany at Singen to produce TAK-003, its dengue vaccine candidate. The Singen vaccine manufacturing facility will be used for the formulation, fill, finish and secondary packaging of the TAK-003 dengue vaccine candidate starting with the packaging line. The vaccine plant employs up to […]

Boehringer Ingelheim to initiate phase 2 trial of BI 456906 in obesity, diabetes

German drugmaker Boehringer Ingelheim will initiate Phase 2 clinical trial of dual-acting GLP-1/glucagon agonist BI 456906 in obesity and diabetes in late 2019. The compound in-licensed from Zealand Pharma is derived from the natural gut hormone oxyntomodulin and activates both the GLP-1 and glucagon receptors to control metabolic activities. The dual agonist BI 456906 with […]

Continue reading …
Bayer to divest animal health business to Elanco for $7.6bn

US-based veterinary pharmaceuticals producer Elanco Animal Health has agreed to acquire German drug giant Bayer’s animal health business for $7.6 billion, financed by a combination of 70% cash and 30% equity. The transaction, which enhances emerging market presence and strengthens cattle business, will strengthen Elanco’s Innovation, Portfolio, and Productivity (IPP) strategy, creating the second largest […]

Continue reading …
Italian pharma company Zambon acquires Breath Therapeutics for €140m

Zambon acquisition of Breath Therapeutics : Italian pharma company Zambon has acquired German biopharma company Breath Therapeutics and its subsidiaries for €140 million, which can potentially go up to total €500 million based on the latter’s achievement of certain regulatory and sales milestones. Breath Therapeutics, which is based in Munich as well as Menlo Park […]

Continue reading …
Aldevron to expand Freiburg antibody development facility

Pharma industry news : US CDMO Aldevron has revealed its plans to expand its antibody development facility in Freiburg, Germany. The Freiburg location of Aldevron is home to the GENOVAC antibody development platform, which became the second site for the US CDMO in 2004. According to Michael Chambers – Aldevron Founding partner and CEO, the […]

Continue reading …
Novus Therapeutics begins phase 1 trial of OP0201 in otitis media

Clinical trial news : Novus Therapeutics has initiated a phase 1 pharmacodynamics clinical trial of its lead candidate OP0201 for the treatment of otitis media, an infection that affects the middle ear. The California-based specialty pharma company, which is focused on developing drugs for ENT disorders, has dosed the first adult patients in the early-stage […]

Continue reading …
Boehringer Ingelheim acquires oncolytic virus company ViraTherapeutics

German pharma company Boehringer Ingelheim has exercised its option to acquire 100% of Austria-based oncolytic virus company ViraTherapeutics for €210 million in a move to develop next generation viral-based immuno-oncology therapies. In September 2016, Boehringer Ingelheim and ViraTherapeutics entered into a long term collaboration to develop the oncolytic virus therapy platform and also to investigate […]

Continue reading …
Humira biosimilar Cyltezo meets objective in phase 3 plaque psoriasis trial

German pharma company Boehringer Ingelheim said that Cyltezo, a biosimilar to AbbVie psoriasis drug Humira, achieved clinical equivalence to the reference product in a phase 3 trial in patients with moderate-to-severe chronic plaque psoriasis. Cyltezo succeeded in the NCT 02850965 phase 3 trial by not showing any clinically meaningful differences in efficacy, safety and immunogenicity […]

Continue reading …
Novartis’ heart failure drug Entresto can be initiated early in hospitalized patients

Swiss drugmaker Novartis unveiled new data on Entresto (sacubitril/valsartan) from a phase 4 study which confirms that the heart failure drug can be initiated early and safely across a broad range of heart failure patients with reduced ejection fraction (HFrEF), whose condition has been stabilized following hospitalization because of an acute heart failure episode. In […]

Continue reading …
BioNTech, Pfizer join forces to develop mRNA-based flu vaccines

BioNTech, a German biotechnology company, has joined forces with US pharma giant Pfizer to develop mRNA-based flu vaccines as part of a $425 million multi-year research and development (R&D) collaboration. As per the terms of the deal, BioNTech and Pfizer will jointly take up research and development activities for advancing mRNA-based vaccines to prevent influenza […]

Continue reading …
Page 1 of 212